Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product

      

Mon, 06 Aug 2007, 19:46:00 EDT
Edited by Liisa Sullivan

RICHMOND, Texas - Aug. 6 (SEND2PRESS NEWSWIRE) -- CYNACON /OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.

RICHMOND, Texas - Aug. 6 (SEND2PRESS NEWSWIRE) -- CYNACON/OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.

(c) Send2PressThe ALODOX(R) Convenience Kit contains ALODOX(R) (Doxycycline Hyclate 20 milligrams); OCuSOFT(R) Lid Scrub(TM) PLUS Extra Strength Pre-Moistened Pads; and OCuSOFT(R) Lid Scrub(TM) Original Foaming Eyelid Cleanser. This new and convenient combination therapy promises to significantly increase patient compliance while improving overall eyelid-hygiene therapy.

OCuSOFT(R) Lid Scrub(TM) PLUS Extra Strength Pre-Moistened Pads is an extra strength eyelid cleanser that uses a low-level preservative and moisturizer blend, offering a wide range of anti-bacterial properties. It is perfect for moderate to severe eyelid conditions.

OCuSOFT(R) Lid Scrub(TM) Original Foaming Eyelid Cleanser is an instant foam liquid that generates pre-lathered foam immediately upon depressing the control-tip pump. The foam formula provides patients who are on a lid-hygiene regimen, with added convenience. It is economical and ideal for shower use.

So, why combine all three? Reports confirm that ALODOX(R) is prescribed much more often than minocycline, partly because it is a more potent collagenase inhibitor.

Therefore, the use of low-dose doxycycline hyclate has demonstrated effective enzyme modulation treatment of inflammatory disease. And, at such low levels - 50 milligrams or less - doxycycline reduces inflammation, yet still maintains maximum plasma drug concentrations below the anti-microbial threshold, resulting in fewer side effects.

"We are excited to be able to offer the ALODOX Convenience Kit for systemic inflammatory relief," Patrick Witham, Executive Vice President, CYNACON/OCuSOFT(R), said. "While traditional doxycycline has been prescribed for years, new research suggests that low-dose doxycycline is just as effective, and without the added side effects such as gastritis and photosensitivity."

Coupled with OCuSOFT(R) Lid Scrub(TM) products, the ALODOX(R) Convenience Kit has a mission that will lead to increased patient satisfaction and compliance.

CYNACON/OCuSOFT(R) (OCuSOFT, Inc.), founded in 1986, is a company dedicated to addressing clinical needs through well-researched and technological solutions. They are dedicated to optimizing the delivery and performance of ophthalmic pharmaceutical products while improving patient care, quality of life, and compliance.

For more information on the ALODOX(R) Convenience Kit, visit: www.alodox.com. To learn more about the company and find out about other available products, visit: www.ocusoft.com.

NEWS SOURCE: CYNACON / OCuSOFT (OCuSOFT, Inc.)

Send2Press® is the originating wire service for this story “Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product” and content is Copr. © 2007 CYNACON / OCuSOFT (OCuSOFT, Inc.) with newswire copy Copr. © 2007 Send2Press (a service of Neotrope). All trademarks acknowledged.

TERMS OF USE: rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
NOTICE: THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE ("CYNACON / OCuSOFT (OCuSOFT, Inc.)"), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS OR CONCERNS ABOUT THIS NEWS ANNOUNCEMENT, PLEASE CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Reads as of Saturday, Apr 19 2014 - 23:58:56 PM EDT:
5606 times (3 today, 6 this week, 28 this month, 129 this year)